Multiple sclerosis and COVID-19
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Review
PubMed
32686774
DOI
10.5507/bp.2020.033
Knihovny.cz E-resources
- Keywords
- COVID-19, coronavirus, immunomodulatory therapy, multiple sclerosis,
- MeSH
- Asymptomatic Diseases epidemiology MeSH
- Autoimmunity MeSH
- Betacoronavirus physiology MeSH
- COVID-19 MeSH
- Immunologic Factors pharmacology MeSH
- Immunomodulation immunology MeSH
- Coronavirus Infections * epidemiology immunology therapy virology MeSH
- Humans MeSH
- Pandemics * MeSH
- Multiple Sclerosis * epidemiology immunology therapy MeSH
- SARS-CoV-2 MeSH
- Pneumonia, Viral * epidemiology immunology therapy virology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Immunologic Factors MeSH
This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).
References provided by Crossref.org
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia
